Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2024 Oct 21;6(10):e1173.
doi: 10.1097/CCE.0000000000001173. eCollection 2024 Oct 1.

Procalcitonin-Guided Management and Duration of Antibiotic Therapy in Critically Ill Cancer Patients With Sepsis (Pro-Can Study): A Randomized Controlled Trial

Lama H Nazer  1 , Wedad Awad  1 , Hadeel Thawabieh  1 , Aseel Abusara  1 , Deema Abdelrahman  1 , Awad Addassi  1 , Osama Abuatta  1 , Maher Sughayer  1 , Yahya Shehabi  2
Affiliations
Randomized Controlled Trial

Procalcitonin-Guided Management and Duration of Antibiotic Therapy in Critically Ill Cancer Patients With Sepsis (Pro-Can Study): A Randomized Controlled Trial

Lama H Nazer et al. Crit Care Explor. .

Abstract

Objectives: To evaluate the effect of procalcitonin-guided management on the duration of antibiotic therapy in critically ill cancer patients with sepsis.

Design: Randomized, controlled, single-blinded trial.

Setting: A comprehensive multidisciplinary cancer hospital in Jordan.

Patients: Adults with cancer treated in the ICU who were started on antibiotics for suspected infection, met the SEPSIS-3 criteria, and were expected to stay in the ICU greater than or equal to 48 hours.

Interventions: Patients were randomized to the procalcitonin-guided or standard care (SC) arms. All patients had procalcitonin measured daily, up to 5 days or until ICU discharge or death. For the procalcitonin arm, a procalcitonin-guided algorithm was provided to guide antibiotic management, but clinicians were allowed to override the algorithm, if clinically indicated. In the SC arm, ICU clinicians were blinded to the procalcitonin levels.

Measurements and main results: Primary outcome was time to antibiotic cessation. We also evaluated the number of antibiotic-free days at 28 days, hospital discharge, or death, whichever came first, and antibiotic defined daily doses (DDDs). We enrolled 77 patients in the procalcitonin arm and 76 in the SC arm. Mean age was 58 ± 14 (sd) years, 67% were males, 74% had solid tumors, and 13% were neutropenic. Median (interquartile range [IQR]) Sequential Organ Failure Assessment scores were 7 (6-10) and 7 (5-9) and procalcitonin concentrations (ng/mL) at baseline were 3.4 (0.8-16) and 3.4 (0.5-26), in the procalcitonin and SC arms, respectively. There was no difference in the median (IQR) time to antibiotic cessation in the procalcitonin and SC arms, 8 (4-11) and 8 (5-13), respectively (p = 0.463). Median (IQR) number of antibiotic-free days were 20 (17-24) and 20 (16-23), (p = 0.484) and total DDDs were 1541.4 and 2050.4 in the procalcitonin and SC arms, respectively.

Conclusions: In critically ill cancer patients with sepsis, procalcitonin-guided management did not reduce the duration of antibiotic treatment.

PubMed Disclaimer

Conflict of interest statement

The authors have disclosed that they do not have any potential conflicts of interest.

Figures

Figure 1.
Figure 1.
Flow diagram of inclusion and exclusion of patients. DNR = do not resuscitate, ID = infectious disease, PCT = procalcitonin, SOFA = Sequential Organ Failure Assessment.
See this image and copyright information in PMC

References

    1. Soares M, Caruso P, Silva E, et al. ; Brazilian Research in Intensive Care Network (BRICNet): Characteristics and outcomes of patients with cancer requiring admission to intensive care units: A prospective multicenter study. Crit Care Med 2010; 38:9–15 - PubMed
    1. Azoulay E, Mokart D, Pène F, et al. : Outcomes of critically ill patients with hematologic malignancies: Prospective multicenter data from France and Beligium—a groupe de recherche respiratoire en réanimation onco-hématologique study. J Clin Oncol 2013; 31:2810–2818 - PubMed
    1. Hawari FI, Nazer LH, Addassi A, et al. : Predictors of ICU admission in patients with cancer and the related characteristics and outcomes: A 5-year registry-based study. Crit Care Med 2016; 44:548–553 - PubMed
    1. Soubani AO: Critical care prognosis and outcomes in patients with cancer. Clin Chest Med 2017; 38:333–353 - PubMed
    1. Nazer L, Lopez-Olivo MA, Cuenca JA, et al. : All-cause mortality in cancer patients treated with sepsis in intensive care units: A systematic review and meta-analysis. Support Care Cancer 2022; 30:10099–10109 - PMC - PubMed

Publication types